Suresh Senan

PROF.DR., (Principal Investigator)

1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

A Primer on Interstitial Lung Disease and Thoracic Radiation

International Association for the Study of Lung Cancer Advanced Radiation Technology Committee, 24 Feb 2020, In : Journal of Thoracic Oncology.

Research output: Contribution to journalReview articleAcademicpeer-review

Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study

Wolff, H. B., Alberts, L., van der Linden, N., Bongers, M. L., Verstegen, N. E., Lagerwaard, F. J., Hofman, F. N., Uyl-de Groot, C. A., Senan, S., El Sharouni, S. Y., Kastelijn, E. A., Schramel, F. M. N. H. & Coupé, V. M. H., Mar 2020, In : Lung Cancer. 141, p. 89-96 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
Open Access

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial

Paz-Ares, L., Spira, A., Raben, D., Planchard, D., Cho, B. C., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., Murakami, S., Spigel, D., Senan, S., Langer, C. J., Boothman, A-M., Broadhurst, H., Wadsworth, C., Dennis, P. A., Antonia, S. J. & Faivre-Finn, C., 21 Mar 2020, In : Annals of oncology : official journal of the European Society for Medical Oncology. 31, 6, 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Park, K., Vansteenkiste, J., Lee, K. H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P. J., Tan, D. S. W., Yang, J. C. H., Wang, J., Babu, K. G., Nakayama, Y., Alip, A., Chua, K. L. M., Cheng, J. C. H., Senan, S., Ahn, Y. C., Kim, T. Y., Ahn, H. K. & 3 others, Peters, S., Yoshino, T. & Douillard, J. Y., 1 Feb 2020, In : Annals of Oncology. 31, 2, p. 191-201 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Points to consider regarding the SABR-COMET trial - Authors' reply

Palma, D. A., Warner, A. & Senan, S., 8 Feb 2020, In : Lancet. 395, 10222, p. e20

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC

Brooks, E. D., Verma, V., Senan, S., De Baere, T., Lu, S., Brunelli, A., Chang, J. Y. & International Association for the Study of Lung Cancer Advanced Radiation Technology Committee, Feb 2020, In : Journal of Thoracic Oncology. 15, 2, p. 176-189 14 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Open Access
Open Access

Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91

de Jong, E. E. C., Guckenberger, M., Andratschke, N., Dieckmann, K., Hoogeman, M. S., Milder, M., Møller, D. S., Nyeng, T. B., Tanadini-Lang, S., Lartigau, E., Lacornerie, T., Senan, S., Verbakel, W., Verellen, D., De Kerf, G. & Hurkmans, C., Jan 2020, In : Radiotherapy and Oncology. 142, p. 217-223 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
2019

ADRIATIC: A phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer

Senan, S., Shire, N., Mak, G., Yao, W. & Jiang, H., Apr 2019, In : Annals of Oncology. 30, p. 25-25

Research output: Contribution to journalMeeting AbstractAcademic

Curative Radiotherapy for Non-small Cell Lung Cancer: Practice Changing and Changing Practice?

Mcdonald, F., Senan, S., Faivre-Finn, C. & Hatton, M., 1 Oct 2019, In : Clinical Oncology. 31, 10, p. 678-680 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Open Access

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report

Dingemans, A-M. C., Hendriks, L. E. L., Berghmans, T., Levy, A., Hasan, B., Faivre-Finn, C., Giaj-Levra, M., Giaj-Levra, N., Girard, N., Greillier, L., Lantuéjoul, S., Edwards, J., O'Brien, M., Reck, M., Smit, E. F., Van Schil, P., Postmus, P. E., Ramella, S., Lievens, Y., Gaga, M. & 18 others, Peled, N., Scagliotti, G. V., Senan, S., Paz-Ares, L., Guckenberger, M., McDonald, F., Ekman, S., Cufer, T., Gietema, H., Infante, M., Dziadziuszko, R., Peters, S., Porta, R. R., Vansteenkiste, J., Dooms, C., de Ruysscher, D., Besse, B. & Novello, S., 1 Dec 2019, In : Journal of Thoracic Oncology. 14, 12, p. 2109-2119 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

Senan, S., Okamoto, I., Lee, G-W., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N., Jiang, H. & Cho, B. C., 28 Dec 2019, In : Clinical Lung Cancer.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Geometric efficacy of breath-hold gated MR-guided SABR for adrenal metastases

de Koste, J. V. S., Palacios, M., Bruynzeel, A., Spoelstra, F., Slotman, B., Lagerwaard, F. & Senan, S., Apr 2019, In : Radiotherapy and Oncology. 133, p. S212-S213

Research output: Contribution to journalMeeting AbstractAcademic

Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer

Govindan, R., Senan, S., Dickgreber, N., Provencio, M., Wu, Y-L., Syrigos, K., Parente, B., Wilson, M., Ziemiecki, R., Chouaki, N., Hossain, A., San Antonio, B., Winfree, K. & Vokes, E. E., 3 Oct 2019, In : Current Medical Research and Opinion. 35, 10, p. 1761-1767 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-Comet

Qu, M. X., Chen, Y., Zaric, G., Senan, S., Olson, R. A., Harrow, S., John-Baptiste, A., Gaede, S., Mulroy, L., Schellenberg, D., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Warner, A., Rodrigues, G., Palma, D. A. & Louie, A. V., 1 Sep 2019, In : International Journal of Radiation Oncology Biology Physics. 105, 1, p. S100-S101

Research output: Contribution to journalMeeting AbstractAcademic

IS SABR COST-EFFECTIVE IN OLIGOMETASTATIC CANCER? AN ECONOMIC ANALYSIS OF SABR-COMET

Qu, M., Chen, Y., Zaric, G., Senan, S., Olson, R., Harrow, S., John-Baptiste, A., Gaede, S., Mulroy, L., Schellenberg, D., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Warner, A., Rodrigues, G., Palma, D. & Louie, A., Oct 2019, In : Radiotherapy and Oncology. 139, p. S41-S42

Research output: Contribution to journalMeeting AbstractAcademic

Open Access

MR-guided adaptive radiotherapy for intra-abdominal lymphoma

Spoelstra, F., Cobussen, P., Palacios, M., Bruynzeel, A., Lagerwaard, F., Slotman, B. & Senan, S., Apr 2019, In : Radiotherapy and Oncology. 133, p. S30-S31

Research output: Contribution to journalMeeting AbstractAcademic

Patient Selection and Early Clinical Outcomes of MR-Guided SABR in 54 Lung Tumors

Finazzi, T., Haasbeek, C., Spoelstra, F., Palacios, M., Admiraal, M., Bruynzeel, A., Slotman, B., Lagerwaard, F. & Senan, S., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. S253-S253

Research output: Contribution to journalMeeting AbstractAcademic

Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)

Raben, D., Rimner, A., Senan, S., Broadhurst, H., Pellas, T., Dennis, P. A. & Faivre-Finn, C., 1 Nov 2019, In : International Journal of Radiation Oncology Biology Physics. 105, 3, p. 683-683

Research output: Contribution to journalMeeting AbstractAcademic

Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial

Olson, R., Senan, S., Harrow, S., Gaede, S., Louie, A., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G., Yaremko, B., Schellenberg, D., Ahmad, B., Griffioen, G., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Bauman, G. & 2 others, Warner, A. & Palma, D., 1 Dec 2019, In : International journal of radiation oncology, biology, physics. 105, 5, p. 943-947 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

QUALITY OF LIFE OUTCOMES AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) VERSUS STANDARD OF CARE PALLIATIVE TREATMENTS: A SECONDARY ANALYSIS OF THE SABR-COMET RANDOMIZED TRIAL

Olson, R., Senan, S., Harrow, S., Gaede, S., Louie, A., Haasbeek, N., Mulroy, L., Lock, M., Rodriques, G., Yaremko, B., Schellenberg, D., Ahmad, B., Griffioen, G., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Bauman, G. & 2 others, Warner, A. & Palma, D., Oct 2019, In : Radiotherapy and Oncology. 139, p. S41-S41

Research output: Contribution to journalMeeting AbstractAcademic

Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial

Olson, R. A., Senan, S., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M. I., Rodrigues, G., Yaremko, B. P., Schellenberg, D., Ahmad, B., Griffioen, G., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Bauman, G. S. & 2 others, Warner, A. & Palma, D. A., 1 Sep 2019, In : International Journal of Radiation Oncology Biology Physics. 105, 1, p. S72-S73

Research output: Contribution to journalMeeting AbstractAcademic

RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

Paz-Ares, L., Senan, S., Planchard, D., Wang, L., Cheong, A., Slepetis, R., Nguyen, M. H. & Vokes, E. E., Apr 2019, In : Annals of Oncology. 30, p. 67-67

Research output: Contribution to journalMeeting AbstractAcademic

SBRT for oligometastatic NSCLC

Senan, S., Apr 2019, In : Radiotherapy and Oncology. 133, p. S356-S356

Research output: Contribution to journalMeeting AbstractAcademic

Stage I (Resectable) NSCLC: Radiation

Senan, S., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. S166-S166

Research output: Contribution to journalMeeting AbstractAcademic

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Palma, D. A., Olson, R., Harrow, S., Correa, R. J. M., Schneiders, F., Haasbeek, C. J. A., Rodrigues, G. B., Lock, M., Yaremko, B. P., Bauman, G. S., Ahmad, B., Schellenberg, D., Liu, M., Gaede, S., Laba, J., Mulroy, L., Senthi, S., Louie, A. V., Swaminath, A., Chalmers, A. & 5 others, Warner, A., Slotman, B. J., de Gruijl, T. D., Allan, A. & Senan, S., 2019, In : BMC Cancer. 19, 1, 816.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., Schellenberg, D., Ahmad, B., Griffioen, G., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Bauman, G. S. & 2 others, Warner, A. & Senan, S., 18 May 2019, In : Lancet. 393, 10185, p. 2051-2058 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Toxicity of Lung SABR in Patients with Coexisting Interstitial Lung Disease

Finazzi, T., Ronden, M., Nossent, E., Tekatli, H., Bahce, I., Slotman, B., Spoelstra, F. & Senan, S., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. S252-S252

Research output: Contribution to journalMeeting AbstractAcademic

Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries

Damhuis, R., Senan, S., Khakwani, A., Harden, S., Helland, A. & Strand, T-E., Apr 2019, In : Annals of Oncology. 30, p. ii27-ii28

Research output: Contribution to journalMeeting AbstractAcademic

Open Access
2018

Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay

Advanced Radiation Technology Committee of the International Association for the Study of Lung Cancer, Jun 2018, In : Journal of Thoracic Oncology. 13, 6, p. 855-862 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer

Wolff, H. B., Alberts, L., Kastelijn, E. A., Lissenberg-Witte, B. I., Twisk, J. W., Lagerwaard, F. J., Senan, S., El Sharouni, S. Y., Schramel, F. M. N. H. & Coupé, V. M. H., May 2018, In : Journal of Thoracic Oncology. 13, 5, p. 689-698 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Early detection of lung cancer recurrence after stereotactic ablative radiation therapy: Radiomics system design

Dammak, S., Palma, D., Mattonen, S., Senan, S. & Ward, A. D., 1 Jan 2018, Medical Imaging 2018: Computer-Aided Diagnosis. SPIE, Vol. 10575. 1057503

Research output: Chapter in Book/Report/Conference proceedingConference contributionAcademicpeer-review

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC

Faivre-Finn, C., Spigel, D. R., Senan, S., Langer, C. J., Raben, D., Perez, B., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., Murakami, S., Paz-Ares, L., Poole, L., Wadsworth, C., Dennis, P. A. & Antonia, S. J., 1 Oct 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii488

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC

Faivre-Finn, C., Spigel, D. R., Senan, S., Langer, C. J., Raben, D., Perez, B., Ozguroglu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., Murakami, S., Paz-Ares, L., Poole, L., Wadsworth, C., Dennis, P. A. & Antonia, S. J., Oct 2018, In : Annals of Oncology. 29, p. 488-488

Research output: Contribution to journalMeeting AbstractAcademic

Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling

Duijm, M., Tekatli, H., Oomen-de Hoop, E., Verbakel, W., Schillemans, W., Slotman, B. J., Senan, S. & Nuyttens, J. J., May 2018, In : Radiotherapy and Oncology. 127, 2, p. 233-238 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Esophagus toxicity after stereotactic radiotherapy of central lung tumor: NTCP modelling

Duijm, M., Tekatli, H., Oomen-de Hoop, E., Verbakel, W., Schillemans, W., Slotman, B. J., Senan, S. & Nuyttens, J. J., Apr 2018, In : Radiotherapy and Oncology. 127, p. S15-S15

Research output: Contribution to journalMeeting AbstractAcademic